Dissemination

Preeclampsia greatly increases severe maternal morbidity risk. Targeted prenatal monitoring is key, especially for patients with chronic hypertension.

Study highlights concerns about premature adoption of preeclampsia screening tests, emphasizing the need for clinical utility trials before widespread implementation.

Physician’s Weekly spoke with Luis Raez, MD, to learn more about an FDA-approved targeted therapy option for patients with advanced ROS1+ NSCLC.

Physician’s Weekly spoke with Debora Bruno, MD, to explore how biomarker testing may guide treatment decisions for patients with advanced ROS1+ NSCLC.

Physician’s Weekly spoke with Edgardo Santos, MD, about the multidisciplinary team’s role in developing treatment plans for patients with advanced ROS1+ NSCLC.

Physician’s Weekly spoke with Whitney Lewis, PharmD, about the evolving role of pharmacists in managing NSCLC.

Recent preeclampsia studies have investigated predictors such as placenta location and PAPP-A, in addition to comparing the P/C ratio with 24-hour proteinuria.

The reasons why preeclampsia and other hypertensive disorders impact up to 8% of pregnancies are not fully understood, prompting calls for further research.

Routine screening for patient-reported outcomes may improve access to supportive care services among long-term metastatic breast cancer survivors.

Elevations in biomarkers such as uterine artery pulsatility index and placental growth factor throughout pregnancy indicate preeclampsia risk.

Findings published in Clinical Epigenetics underscore the impact of differentially methylated regions in pregnancy complications, including preeclampsia.

Genomic profiling in the FLEX trial predicted chemotherapy response in HR+, HER2- breast cancer, which could enable tailored treatment plans.

Justin Balko, PharmD, PhD, reviews his session from SABCS 2024 where he discussed the challenges and advancements in immunotherapy for early-stage triple-negative breast cancer (TNBC). Additionally, he discusses the importance of identifying predictive biomarkers to optimize treatment and improve patient quality of life.

Physician’s Weekly spoke with Dr. Otsubo and Dr. Hara about their research and how they anticipate the SDB kit will be applied in clinical settings.

Justin Balko, PharmD, PhD, recently joined Dr. Priyanka Sharma and Dr. Roberto Salgado at the 2024 San Antonio Breast Cancer Symposium to discuss immune biomarkers, including tumor-infiltrating lymphocytes, and their roles.

Dr. Marla Lipsyc-Sharf reviews her recent session at the 2024 SABCS meeting, discussing biopsy approaches and treatment sequencing in metastatic breast cancer.

Oncologist Marla Lipsyc-Sharf, MD, and colleagues will discuss treatment considerations in metastatic ER+ breast cancer at the 2024 SABCS meeting.

This roundup includes a selection of abstracts on early and metastatic breast cancer presented at the 2024 San Antonio Breast Cancer Symposium.

Will you be attending “Case Based Clinical Approach to ER Positive Metastatic Breast Cancer” on Wednesday, December 11?

This roundup offers a look at the latest insights from the clinicians and researchers investigating chronic obstructive pulmonary disease and asthma.